Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.62 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836914 | 1.00 | SLC5A2 (0.62) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL15836819 | 0.90 | SLC5A2 (0.58) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL5020077 | 0.85 | SLC5A2 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL15836921 | 0.84 | SLC5A2 (0.61) | SLC5A2SLC5A1 | |
| SCHEMBL20211039 | 0.84 | SLC5A2 (0.61) | SLC5A2SLC5A1 | |
| SCHEMBL15825405 | 0.83 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL20221153 | 0.83 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL15836920 | 0.83 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL15836917 | 0.83 | SLC5A2 (0.58) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| SCHEMBL20211013 | 0.83 | SLC5A2 (0.58) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388441-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-2935302-B1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMA (US) | 2018-06-06 | — | — | EP | disclosed |